301
Participants
Start Date
February 28, 2010
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
Sarilumab
"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
Placebo
"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
Investigational Site Number 056003, Brussels
Investigational Site Number 348001, Budapest
Investigational Site Number 040002, Vienna
Investigational Site Number 056002, Leuven
Investigational Site Number 036001, Malvern East
Investigational Site Number 056005, Genk
Investigational Site Number 348005, Sátoraljaújhely
Investigational Site Number 056004, Liège
Investigational Site Number 348003, Debrecen
Investigational Site Number 036002, Woolloongabba
Investigational Site Number 036004, Shenton Park
Investigational Site Number 036003, Hobart
Investigational Site Number 040001, Graz
Investigational Site Number 348004, Veszprém
Investigational Site Number 056001, Ghent
Investigational Site Number 276002, Berlin
Investigational Site Number 840016, Albany
Investigational Site Number 203001, Prague
Investigational Site Number 840036, Syracuse
Investigational Site Number 724004, A Coruña
Investigational Site Number 840014, Duncansville
Investigational Site Number 840023, Bethlehem
Investigational Site Number 840003, Wheaton
Investigational Site Number 276005, Hamburg
Investigational Site Number 840034, Chesapeake
Investigational Site Number 250001, Besançon
Investigational Site Number 724002, Madrid
Investigational Site Number 840032, Orlando
Investigational Site Number 250005, Bordeaux
Investigational Site Number 840009, Boca Raton
Investigational Site Number 840001, Naples
Investigational Site Number 840006, Birmingham
Investigational Site Number 792001, Izmir
Investigational Site Number 724001, Seville
Investigational Site Number 840010, Toledo
Investigational Site Number 276001, Herne
Investigational Site Number 840008, Lansing
Investigational Site Number 203002, Hradec Králové
Investigational Site Number 276003, Frankfurt am Main
Investigational Site Number 840021, Rock Island
Investigational Site Number 840002, St Louis
Investigational Site Number 203003, Brno
Investigational Site Number 203004, Uherské Hradiště
Investigational Site Number 840005, Oklahoma City
Investigational Site Number 203005, Hlučín
Investigational Site Number 250003, Paris
Investigational Site Number 840004, Dallas
Investigational Site Number 840030, Houston
Investigational Site Number 840015, Boise
Investigational Site Number 840027, Los Angeles
Investigational Site Number 276004, Erlangen
Investigational Site Number 840017, Upland
Investigational Site Number 840007, San Diego
Investigational Site Number 840033, Anaheim
Investigational Site Number 250002, Créteil
Investigational Site Number 840013, San Francisco
Investigational Site Number 840018, Kansas City
Investigational Site Number 840029, Worcester
Investigational Site Number 840028, Freehold
Investigational Site Number 124007, London
Investigational Site Number 124004, Montreal
Investigational Site Number 124008, Newmarket
Investigational Site Number 124003, Pointe-Claire
Investigational Site Number 124001, Québec
Investigational Site Number 124006, Saskatoon
Investigational Site Number 124005, Toronto
Investigational Site Number 124009, Trois-Rivières
Investigational Site Number 124002, Vancouver
Investigational Site Number 124010, Vancouver
Investigational Site Number 440001, Kaunas
Investigational Site Number 440002, Vilnius
Investigational Site Number 528001, Amsterdam
Investigational Site Number 528002, Nijmegen
Investigational Site Number 616002, Bialystok
Investigational Site Number 616001, Krakow
Investigational Site Number 616004, Lublin
Investigational Site Number 616005, Torun
Investigational Site Number 616003, Warsaw
Investigational Site Number 724005, Barcelona
Investigational Site Number 792002, Ankara
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY